Lamellar sliver: devastating complication of recutting after LASIK

Article

A lamellar sliver is a devastating complication resulting from recutting flaps during LASIK enhancement procedures.

A lamellar sliver is a devastating complication resulting from recutting flaps during LASIK enhancement procedures, said Jonathan Song, MD, from the Doheny Eye Institute, Los Angeles, US.

Retreatment, he noted, is needed in 3–10% of patients who undergo LASIK. After LASIK was initially introduced, recutting was advised after six months; later, relifting was advised after one year and then after two years. However, a serious complication, lamellar sliver, which is tissue missing from the flap as a result of recutting, was reported to have caused irregular astigmatism and decreased visual acuity. Twelve patients were found to have this complication after procedures performed by nine experienced surgeons; all patients had irregular astigmatism, significant loss of best-corrected visual acuity, and very high subjective visual difficulties.

To prevent the lamellar sliver, Dr Song advised surgeons to relift all flaps if possible - relifting can be done up to 10 years using a needle or a depression technique.

“The technique that I prefer in patients with a relatively new flap is where the edge of the flap can be depressed and a blunt instrument used to go inside the edge,” he said. “A spatula can be used to loosen any adhesion.”

After retreatment, the edges should be clean and any loose epithelium removed. A bandage contact lens can be considered. If the flap is difficult to lift, he suggested converting to surface ablation with mitomycin C.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.